iNtRON Biotechnology has announced that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF, a harmful microbe associated with colorectal cancer.
iNtRON Biotechnology has announced that New Drug Part has secured a potent anti-cancer candidate, PHAGERIA®, with broad antimicrobial activity against ETBF, a harmful microbe associated with colorectal cancer.